Acrisorcin

CHEMBL1201038 Phase 4 Onaylandı Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
388.5 g/mol
LogP
Phase
4

A topical antifungal agent used historically to treat tinea versicolor, a fungal skin infection that causes patches of discolored skin on the trunk and shoulders. It works by disrupting the cell membrane of the yeast responsible for the infection. It is rarely used today, having been largely supplanted by more effective and better-tolerated topical and oral antifungal treatments.

Moleküler Ağırlık

388,5000 g/mol

TPSA

79,40 Ų

Etki Mekanizması

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

2D Yapı

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCCCCCc1ccc(O)cc1O.Nc1c2ccccc2nc2ccccc12

InChI

InChI=1S/C13H10N2.C12H18O2/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13;1-2-3-4-5-6-10-7-8-11(13)9-12(10)14/h1-8H,(H2,14,15);7-9,13-14H,2-6H2,1H3

Molecular Formula

C25H28N2O2

HBD / HBA

3 / 4

Döndürülebilir Bağlar

5

Ağır Atomlar

29

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

A topical antifungal agent used historically to treat tinea versicolor, a fungal skin infection that causes patches of discolored skin on the trunk and shoulders. It works by disrupting the cell membrane of the yeast responsible for the infection. It is rarely used today, having been largely supplanted by more effective and better-tolerated topical and oral antifungal treatments.

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Yes, Acrisorcin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201038. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 24144. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.